# US 2024/0390443 A1 · Natural cluster or formulation containing bixa orellana oil with a standardized tocotrienol content, dry myrciaria dubia extract with a standardized ascorbic acid content and soy germ with a standardized isoflavone content, method for preparing same and use thereof for the support treatment of menopause symptoms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390443 A1
- Document ID: US20240390443A1
- Status: Published application
- Kind: A1
- Application number: 18/688,596
- Filed: 2022-09-01
- Published: 2024-11-28
- Earliest claimed: 2021-09-02
- Assignees: José Carlos TAVARES CARVALHO; Agmont, Carvalho E Bustamante Comercio De Produtos Naturais S.A.
- Applicants: Agmont, Carvalho E Bustamante Comercio De Produtos Naturais S.A.
- Inventors: José Carlos TAVARES CARVALHO; ALINE LOPES DO NASCIMENTO; Heitor RIBEIRO DA SILVA; Osvaldo Alejandro ESPINOLA BUSTAMANTE; Abrahão Victor TAVARES DE LIMA TEIXEIRA DOS S; Andreia Thais DA SILVA MONTE; Clarice FLEXA ROCHA
- Web page: https://patentgrep.com/patent/US20240390443A1

## CPC

- A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61P 15/12: for climacteric disorders
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/375: Ascorbic acid, i.e. vitamin C; Salts thereof
- A61K 31/685: one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K 36/61: Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
- A61K 36/899: Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61P 19/10: for osteoporosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The natural cluster or formulation containing oil from Bixa orellana standardized in tocotrienols, dry extract of Myrciaria dubia standardized in ascorbic acid and soy germ standardized in isoflavones for the supportive treatment for menopause and action on osteoporosis pertains to the technical sector of Pharmaceutical, Phytotherapeutic, Food Supplements and Nutraceuticals. The invention is developed according to techniques established in the scientific environment both for its preparation and for the quality control thereof, containing raw materials derived from nature. The cluster is in the form of granules and/or fine powder which is obtained after systematically mixing the components and industrial validation. The invention has an adequate release for what is expected for the form of the product and optimal flow properties. The process for the preparation of said natural cluster or formulation is also described.

## Claims

### Claim 1

A natural formulation or cluster comprising 35-45% of oil from Bixa orellana standardized in tocotrienols, 1-5% of lecithin, 1-5% of dry extract of Myrciaria dubia standardized in ascorbic acid, and 15-25% of soy germ standardized in isoflavones, and 20-48% of excipients by weight relative to the total weight of the natural formulation or cluster.

### Claim 2 (depends on 1)

The natural formulation or cluster according to claim 1 wherein the oil from Bixa orellana standardized in tocotrienols is obtained by the process of alkaline lixiviation from the seeds, and the dry extract of Myrciaria dubia is obtained by standard drying in Spray Dryer, and the soy germ is obtained by pressing.

### Claim 3 (depends on 1)

The natural formulation or cluster according to claim 1 wherein the lecithin is sunflower lecithin.

### Claim 4 (depends on 1)

The natural formulation or cluster according to claim 1 wherein the excipients are corn starch, maltodextrin, microcrystalline cellulose, and silicon dioxide.

### Claim 5 (depends on 1)

The natural formulation or cluster according to claim 1 further comprising the oil from Bixa orellana standardized in tocotrienols with a reference chemical composition of 1-5% Bixin, 5-15% tocotrienols as compounds of interest, dry extract of Myrciaria dubia standardized in ascorbic acid between 1 and 4.5%, and the soy germ standardized in isoflavones between 4 and 8%, where the above values are expressed in w/w.

### Claim 6 (depends on 1)

The natural formulation or cluster according to claim 1 having a pH between 5.0 and 9.0.

### Claim 7 (depends on 1)

The natural formulation or cluster according to claim 1 used in the supportive treatment of menopause symptoms and action on osteoporosis.

### Claim 8 (depends on 1)

The natural formulation or cluster according to claim 1 having a final form of a granulate and/or fine powder.

### Claim 9 (depends on 1)

The natural formulation or cluster according to claim 1 in the form of capsules, tablets, powder, or any other pharmaceutical form of controlled release or not.

### Claim 10 (depends on 1)

The method for producing the natural formulation or cluster as defined in claim 1 comprising the following steps:
a) dispersion and homogenization of the lecithin in the standardized oil of Bixa orellana, where the amount of standardized oil should be weighed first, and then the lecithin is added; and
b) incorporation of the solid components into the oil/lecithin mixture
where the ingredients in the powder form are weighed separately and then mixed altogether and homogenized intensely so that only after this procedure they are mixed with the oil/lecithin to obtain a compact mass and the process of preparing the mass is carried out through the incorporation of small quantities of the powder mixture onto the oil/lecithin mixture followed by slow mixing.

### Claim 11 (depends on 10)

The method according to claim 10 wherein the lecithin is sunflower lecithin.

### Claim 12 (depends on 10)

The method according to claim 10 wherein the mixture of steps a) and b) is performed in a planetary mixer.

### Claim 13 (depends on 10)

The method according to claim 10 wherein the powder components consist of soy germ standardized in isoflavones, dry extract of M. dubia standardized in ascorbic acid accordingly, and excipients.

### Claim 14 (depends on 10)

The method according to claim 10 wherein the excipients are corn starch, maltodextrin, microcrystalline cellulose, and silicon dioxide.

### Claim 15 (depends on 1)

A method of treating menopause symptoms and/or osteoporosis comprising administering the natural formulation or cluster as defined in claim 1 to a subject in need thereof.
